Russell Pachynski
@RPachynski
Followers
828
Following
8K
Media
65
Statuses
2K
Associate Professor, Director of GU Oncology Research, Division of Oncology, Washington University STL; Tumor immunology/immunotherapy; views my own
Joined October 2019
@scserendipity1 @aadel_chaudhuri @MayoRadOnc Aadel, I had to search far and wide for a party hat large enough to honor your birthday, but I think I finally pulled it off 🎉🥳
0
0
0
New consensus work on prostate cancer patients with biochemical recurrence #BCR led by @Dr_RaviMadan @davidjeinstein thanks as well to all our @SitemanCenter patients who helped make this possible!
.@theNCI's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. Co-authored by @davidjeinstein and @Dr_RaviMadan. Read the full article. https://t.co/2VErPOonZ1
#prostatecancer #pcsm
0
0
0
Truly a team effort, spanning institutions and disciplines @melissaabel20 @Dr_JeannyAC @ArlenParlen @karen_autio @mbilusic @PChoyke @DeborahCitrin @JulieGr28180604 @FatimaKarzai @MarkowskiGUOnc @CathyHandy @RPachynski @krishnan_patel @EdwinPosadasMD @laurasenamd @xiaoweimd
.@theNCI's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. Co-authored by @davidjeinstein and @Dr_RaviMadan. Read the full article. https://t.co/2VErPOonZ1
#prostatecancer #pcsm
1
3
5
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Einstein discusses: Prostate Cancer.
0
13
17
thanks @Dr_RaviMadan and @davidjeinstein for leading the group- important work that we need to make sure providers are aware of to minimize overtreatment of these patients. 🙏🏼@SitemanCenter @washumedicine
@DrYukselUrun @theNCI @DrMHofman @AzadOncology @Silke_Gillessen @neerajaiims @ZilliThomas @piet_ost @yekeduz_emre @declangmurphy @dmukherji @GGiannarini Thanks 🎈Excellent members on the working group who understand nuances of BCR 🎈Pragmatic recommendations in the context of existing data @davidjeinstein
#BCR #ProstateCancer #PSMA+BCR 🔗Link to 📖 article @JCO_ASCO @ASCO
https://t.co/ePbf8j7KQU
1
0
1
One of the best meetings, consistently…great science, great friends, great foundation! 🎉 thanks @PCFnews #PCFRetreat25
The 32nd Annual #PCFRetreat25 brought together the brightest minds in #ProstateCancer research to discuss groundbreaking science, collaboration and innovation. Here's to continued breakthroughs in research ahead. #Research #Innovation #ThinkTank
0
1
4
BCR prostate cancer: EMBARK for all? Here are some nuances to consider before offering long-term systemic therapy in this setting… @Dr_RaviMadan @DanaFarber_GU @BIDMC_CancerCtr @urotoday @PCF_Science @pca See also
ascopubs.org
PURPOSEBiochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasens...
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Einstein discusses: Prostate Cancer.
1
11
19
In celebration of the 10th Anniversary of the PCF Women in Science/GENI Forum, we are proud to honor Dr. Maha Hussain with the 2025 PCF Women in Science Lifetime Achievement Award. Join as we celebrate her and her achievements. Read more: https://t.co/yGE3Ub76m8
0
8
34
A great leader in the field! 🤩🎉
Congratulations to the legend, Dr. Maha Hussain, on receiving the @PCFnews Lifetime Achievement Award at #PCFRetreat25 👏 From groundbreaking drug approvals in #prostatecancer to an extraordinary legacy of mentorship—so fortunate to call you my mentor.@UroToday @PCF_Science
0
0
4
#EMBARK didn’t write the book📕on #BCR📈#ProstateCancer-it is merely the first chapter What do #BCR trials look like in the #PSMA🩻era? 30+experts met @theNCI🏛️ to provide a roadmap🧭 @JCO_ASCO @ASCO @PCF_Science @APCCC_Lugano @urotoday
https://t.co/ePbf8j7KQU
ascopubs.org
PURPOSEBiochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasens...
1
19
46
Lots @#ESMO25 re:#BCR #ProstateCancer but over-treatment of this indolent disease remains an important issue How does #PSMA imaging factor in? See poster #2393P presented by @HelenMoonMD Saturday +PSMA findings in BCR pts shouldn’t be the reason to treat as rPD is rare @1yr
3
15
33
This will kill people
Trump: DON’T TAKE TYLENOL. There is no downside. You will be uncomfortable, it won't be as easy
781
2K
21K
We had the honor of hosting @PatrickHwuMD, president and CEO of @MoffittNews, at @UF today for an incredible talk on next-generation T-cell therapies for cancer. It was an inspiring and motivating way to kick off our fall Oncology Grand Rounds series. Thank you so much, Dr. Hwu!
4
8
28
A must listen!! …and- can’t wait for #SITC2025 @sitcancer with #TheCheckPoints 🎉🎉🎉 @PatrickHwuMD @jasonlukemd @ipimama123 @FerranPrat5
Tune into The ImmunoVerse, hosted by Moffitt President and CEO @PatrickHwuMD!
1
0
6
Out in DC for @TotalHealthConf …catching up with @Dr_RaviMadan …deep into #ProstateCancer 🤣 @SitemanCenter @theNCI
1
0
15
GU-fantastic this year holy cow! 🤩🤩🤩…congrats to all! 🎉
@montypal @WalterStadler5 @cityofhope @umangtalking @huntsmancancer @utswcancer @apolo_andrea @theNCI @YJanjigianMD @DevikaDasMD @ErikaHamilton9 Thanks @montypal — yes so many GU and @ASCO friends on this list!
0
0
5
can’t wait to see it! 🤗👍🏼
Excited to join The Daily Show tonight with Jon Stewart, looking forward to a fun conversation! @TheDailyShow
0
0
2
congrats! 🎉💪🏼👍🏼
@PGrivasMDPhD @BladderCancerUS @fredhutch @HutchPresident @nicoleflemingmd @RahulBanerjeeMD @OncoAlert @FaltasLab Appreciate your kind works @PGrivasMDPhD. We have much more to do.
0
0
2
Germline genetic variation has been linked to both hematologic cancer and clonal hematopoiesis. But does germline variation influence the likelihood of CH progressing to cancer? And if so, why? We tackle these questions here in @NatureGenet
https://t.co/oICxxJHhI3
nature.com
Nature Genetics - The relationship between pathogenic germline variation, clonal hematopoiesis (CH) and risk of hematologic malignancy is explored in 731,835 individuals across 6 cohorts. Carriers...
12
31
102